Cordeiro I, Duarte A C, Ferreira J F, Gonçalves M J, Meirinhos T, Rocha T M, Romão V C, Sousa S, Guedes M, Conde M, Abreu C, Aleixo M J, Santos M J
Acta Reumatol Port. 2016 Apr-Jun;41(2):112-30.
Serious infections are a major cause of morbidity and mortality in systemic inflammatory rheumatic disease (SIRD) patients. Although vaccination may prevent numerous infections, vaccination uptake rates are low in this group of patients.
To develop evidence-based recommendations for vaccination in SIRD patients.
We searched MEDLINE (until 31 October 2014) and EMBASE (until 14 December 2014) databases, as well as the ACR and EULAR congress abstracts (2011-2014). Patients with any systemic inflammatory rheumatic disease were included and all vaccines were considered. Any safety and efficacy outcomes were admitted. Search results were submitted to title and abstract selection, followed by detailed review of suitable studies. Data were subsequently pooled according to the type of vaccine and the SIRD considered. Results were presented and discussed by a multidisciplinary panel and systematic literature review (SLR)-derived recommendations were voted according to the Delphi method. The level of agreement among rheumatologists was assessed using an online survey.
Eight general and seven vaccine-specific recommendations were formulated. Briefly, immunization status should routinely be assessed in all SIRD patients. The National Vaccination Program should be followed and some additional vaccines are recommended. To maximize the efficacy of vaccination, vaccines should preferably be administered 4 weeks before starting immunosuppression or, if possible when disease activity is controlled. Non-live vaccines are safe in SIRD, including immunosuppressed patients. The safety of live attenuated vaccines in immunosuppressed patients deserves further ascertainment, but might be considered in particular situations.
The present recommendations combine scientific evidence with the multidisciplinary expertise of our taskforce panel and attained desirable agreement among Portuguese rheumatologists. Vaccination recommendations need to be updated on a regular basis, as more scientific data regarding vaccination efficacy and safety, emergent infectious threats, new vaccines as well as new immunomodulatory therapies become available.
严重感染是系统性炎症性风湿疾病(SIRD)患者发病和死亡的主要原因。尽管接种疫苗可预防多种感染,但该类患者的疫苗接种率较低。
制定基于证据的SIRD患者疫苗接种建议。
我们检索了MEDLINE数据库(截至2014年10月31日)、EMBASE数据库(截至2014年12月14日)以及美国风湿病学会(ACR)和欧洲抗风湿病联盟(EULAR)大会摘要(2011 - 2014年)。纳入患有任何系统性炎症性风湿疾病的患者,并考虑所有疫苗。纳入任何安全性和有效性结果。检索结果先进行标题和摘要筛选,然后对合适的研究进行详细审查。随后根据疫苗类型和所考虑的SIRD对数据进行汇总。由多学科小组展示和讨论结果,并根据德尔菲法对系统文献综述(SLR)得出的建议进行投票。通过在线调查评估风湿病学家之间的共识水平。
制定了八项一般性建议和七项疫苗特异性建议。简而言之,应定期评估所有SIRD患者的免疫状态。应遵循国家疫苗接种计划,并推荐一些额外的疫苗。为使疫苗接种效果最大化,疫苗最好在开始免疫抑制前4周接种,或者在疾病活动得到控制时尽可能接种。非活疫苗在SIRD患者中是安全的,包括免疫抑制患者。减毒活疫苗在免疫抑制患者中的安全性值得进一步确定,但在特定情况下可考虑使用。
本建议将科学证据与我们工作组专家小组的多学科专业知识相结合,并在葡萄牙风湿病学家中达成了理想的共识。随着关于疫苗接种效果和安全性、新出现的感染威胁、新疫苗以及新的免疫调节疗法的更多科学数据出现,疫苗接种建议需要定期更新。